A Phase 3 interventional study of elamipretide and placebo comparator in Primary Mitochondrial Myopathy, sponsored by Stealth BioTherapeutics Inc.. Terminated at 27 sites in 7 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-01-24.
Sponsored by Stealth BioTherapeutics Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.
Among the 99 studies in Muscular Diseases with a site in United States, this one is the 12th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2017, is one of 14 in phase 3, and was the 51st registered.
232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.
Browse Muscular Diseases studies →19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
University of Alabama at Birmingham · Sites in United States
Ages 16+
AstraZeneca · Sites in United States, Canada, China and 7 more countries
Ages 18–70
Kite, A Gilead Company · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 18 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 38 across 134 interventional studies indexed under Muscular Diseases.
Median enrollment 38 across the 66 interventional studies, 70 across the 30 observational. Of the 63 that completed or were terminated, 31 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 99 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 2 studies filed under Muscular Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Muscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06599697University of Alabama at BirminghamThe MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | 2026-12-30 |
| NCT06374719Clinic for Special ChildrenWiTNNess - TNNT1 Myopathy Natural History Study | 2027-01-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT02842424University of NebraskaRamipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 99 studies in Muscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy. This will be followed by an open-label treatment extension.
Part 11 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled assessment of the efficacy and safety of single daily subcutaneous (SC) doses of 40 mg elamipretide (vs placebo) administered with the elamipretide delivery system as a treatment for subjects with primary mitochondrial myopathy (PMM). Part 2 was to assess the long-term safety and tolerability of single daily SC doses of 40 mg elamipretide administered with the elamipretide delivery system for up to 144 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PART 1:
Inclusion Criteria:
Exclusion Criteria:
evidence of acute ischemia, atrial fibrillation, or active conduction system abnormalities with the exception of any of the following:
PART 2:
Continuation Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg (0.5mL) elamipretide subcutaneous (SC) daily
Combination Product: elamipretide
Placebo SC daily
Combination Product: placebo comparator
Elamepretide 40 mg (0.5 mL) SC daily
Combination Product: elamipretide open label treatment
40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
Also known as: MTP-131
40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
Also known as: Placebo
40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
Six-minute Walk Test (6MWT)
Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit
Time frame: Baseline to 24 weeks
Total Fatigue Score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
Change from Baseline in Total fatigue score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) by visit. Each individual item score ranges from 1 (none) to 4 (severe). The total fatigue score ranges from 4-16. Lower values represent a better outcome. The total fatigue score is the sum of question 1 through question 4 on the Primary Mitochondrial Myopathy Symptom Assessment.
Time frame: Baseline to 24 weeks
Fatigue During Activities Score on the Primary Mitochondrial Disease Symptom Assessment (PMMSA).
Change from baseline in Fatigue During Activities. Fatigue During Activities is the sum of question 2 (tiredness during activities) and question 4 (muscle weakness during activities.) The four response options are: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Raw scores for each subject range from 2-8. A lower score means a better outcome, with less fatigue. A higher score means a worse outcome, with more fatigue.
Time frame: Baseline to 24 weeks
Neuro-QoL Fatigue Activities of Daily Living
Change From Baseline in Neuro-QoL Fatigue Activities of Daily Living by Visit. Each individual item score ranges from 1-5. Total raw score for the entire item bank ranges from 19-95. Raw scores will be calibrated using Item Response Theory Model. Lower values represent a better outcome. Individual items will be summed to calculate total scores.
Time frame: Baseline to 24 weeks
Change From Baseline in the Most Bothersome Symptom Score on the Primary Mitochondrial Myopathy Symptoms Assessment
The item score rangers from 1 (none) to 4 (severe). Lower values represent a better outcome. The most bothersome score is the average of the identified most bothersome symptom of the Primary Mitochondrial Myopathy Symptom Assessment by each subject.
Time frame: Baseline to 24 weeks
Neuro-QoL Fatigue Short Form Score
Change From Baseline in Neuro-QoL Fatigue - Short Form: Total T-Scores by Visit. The Neuro-QoL Fatigue Short Form is comprised of the sum of the first 8 questions of the Neuro-QoL Item Bank v1.0 - Fatigue. Each question is scored as following: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always. The questions include: I felt exhausted, I felt that I had no energy, I felt fatigued, I was too tired to do my household chores, I was too tired to leave the house, I was frustrated by being too tired to do the things I wanted to do, I felt tired, and I had to limit my social activity because I was tired. T-scores are calculated from the short form scoring table provided by the instrument authors (Neuro-QoL User Manual, 2015). T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Change from baseline: Negative numbers mean less fatigue, better outcome, positive score means more fatigue, worse outcome.
Time frame: 24 Weeks
| Milestone | Double-Blind Elamipretide, Then Open Label Elamepretide | Double-Blind Placebo Then Open-Label Elamepretide |
|---|---|---|
| Started | 109 | 109 |
| Completed | 102 | 103 |
| Not completed | 7 | 6 |
| Withdrew: Lost to follow-up | 4 | 5 |
| Withdrew: Adverse event | 3 | 1 |
| Milestone | Double-Blind Elamipretide, Then Open Label Elamepretide | Double-Blind Placebo Then Open-Label Elamepretide |
|---|---|---|
| Started | 93 | 103 |
| Completed | 0 | 0 |
| Not completed | 93 | 103 |
| Withdrew: Termination of the clinical development of elamipretide in subjects with pmm | 83 | 88 |
| Withdrew: Adverse event | 3 | 10 |
| Withdrew: Withdrawal by subject | 7 | 5 |
Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit
| meters | Elamipretide | Placebo |
|---|---|---|
| Week 4 | 16.243 ± 42.0071 | 7.811 ± 39.5737 |
| Week 12 | 18.286 ± 47.7766 | 8.801 ± 52.1093 |
| Week 24 | 15.330 ± 61.4860 | 17.386 ± 51.6956 |
Change from Baseline in Total fatigue score on the on the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) by visit. Each individual item score ranges from 1 (none) to 4 (severe). The total fatigue score ranges from 4-16. Lower values represent a better outcome. The total fatigue score is the sum of question 1 through question 4 on the Primary Mitochondrial Myopathy Symptom Assessment.
| score on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -1.01 ± 1.714 | -1.08 ± 1.865 |
| Week 12 | -1.08 ± 1.775 | -1.26 ± 2.259 |
| Week 24 | -1.18 ± 2.132 | -1.09 ± 2.443 |
Change from baseline in Fatigue During Activities. Fatigue During Activities is the sum of question 2 (tiredness during activities) and question 4 (muscle weakness during activities.) The four response options are: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Raw scores for each subject range from 2-8. A lower score means a better outcome, with less fatigue. A higher score means a worse outcome, with more fatigue.
| score on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -0.48 ± 0.890 | -0.60 ± 0.998 |
| Week 12 | -0.57 ± 0.923 | -0.67 ± 1.199 |
| Week 24 | -0.64 ± 1.151 | -0.59 ± 1.360 |
Change From Baseline in Neuro-QoL Fatigue Activities of Daily Living by Visit. Each individual item score ranges from 1-5. Total raw score for the entire item bank ranges from 19-95. Raw scores will be calibrated using Item Response Theory Model. Lower values represent a better outcome. Individual items will be summed to calculate total scores.
| score on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -2.5 ± 5.33 | -2.7 ± 5.31 |
| Week 12 | -2.9 ± 6.00 | -2.9 ± 5.13 |
| Week 24 | -2.7 ± 6.06 | -2.1 ± 5.39 |
The item score rangers from 1 (none) to 4 (severe). Lower values represent a better outcome. The most bothersome score is the average of the identified most bothersome symptom of the Primary Mitochondrial Myopathy Symptom Assessment by each subject.
| score on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -0.21 ± 0.492 | -0.24 ± 0.535 |
| Week 12 | -0.24 ± 0.535 | -0.34 ± 0.656 |
| Week 24 | -0.25 ± 0.618 | -0.30 ± 0.713 |
Change From Baseline in Neuro-QoL Fatigue - Short Form: Total T-Scores by Visit. The Neuro-QoL Fatigue Short Form is comprised of the sum of the first 8 questions of the Neuro-QoL Item Bank v1.0 - Fatigue. Each question is scored as following: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always. The questions include: I felt exhausted, I felt that I had no energy, I felt fatigued, I was too tired to do my household chores, I was too tired to leave the house, I was frustrated by being too tired to do the things I wanted to do, I felt tired, and I had to limit my social activity because I was tired. T-scores are calculated from the short form scoring table provided by the instrument authors (Neuro-QoL User Manual, 2015). T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Change from baseline: Negative numbers mean less fatigue, better outcome, positive score means more fatigue, worse outcome.
| score on a scale | Elamipretide | Placebo |
|---|---|---|
| Week 4 | -3.37 ± 5.077 | -2.89 ± 5.915 |
| Week 12 | -3.43 ± 5.681 | -3.60 ± 5.614 |
| Week 24 | -2.68 ± 5.769 | -2.61 ± 5.773 |
Collected over Double-blind period: 24 weeks and continued with Open-label period: up to 144 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Elamipretide | 0/109 (0%) | 5/109 (4.6%) | 107/109 (98.2%) |
| Double-Blind Placebo | 0/109 (0%) | 3/109 (2.8%) | 83/109 (76.1%) |
| Open-Label Elamipretide | 0/93 (0%) | 12/93 (12.9%) | 88/93 (94.6%) |
| Open-Label Placebo | 0/103 (0%) | 9/103 (8.7%) | 102/103 (99%) |
| Event | Double-Blind Elamipretide | Double-Blind Placebo | Open-Label Elamipretide | Open-Label Placebo |
|---|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/109 | 0/109 | 0/93 | 2/103 |
| Suicidal IdeationPsychiatric disorders | 1/109 | 0/109 | 1/93 | 0/103 |
| Psychogenic seizureNervous system disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Humerus fractureInjury, poisoning and procedural complications | 0/109 | 0/109 | 1/93 | 0/103 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Acute myocardial infarctionCardiac disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Coronary artery dissectionCardiac disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Chest painGeneral disorders | 0/109 | 0/109 | 1/93 | 0/103 |
| Event | Double-Blind Elamipretide | Double-Blind Placebo | Open-Label Elamipretide | Open-Label Placebo |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 94/109 | 31/109 | 66/93 | 87/103 |
| Injection site pruritusGeneral disorders | 82/109 | 10/109 | 57/93 | 81/103 |
| Injection site indurationGeneral disorders | 31/109 | 6/109 | 25/93 | 41/103 |
| Injection site painGeneral disorders | 43/109 | 20/109 | 32/93 | 37/103 |
| Injection site swellingGeneral disorders | 42/109 | 7/109 | 29/93 | 20/103 |
| injection site bruisingGeneral disorders | 9/109 | 18/109 | 5/93 | 15/103 |
| injection site urticariaGeneral disorders | 14/109 | 0/109 | 12/93 | 8/103 |
| injection site noduleGeneral disorders | 11/109 | 2/109 | 8/93 | 8/103 |
| injection site haemorrhageGeneral disorders | 7/109 | 10/109 | 2/93 | 8/103 |
| EosinophiliaBlood and lymphatic system disorders | 0/109 | 0/109 | 1/93 | 9/103 |
| Age, Customized(years) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Years, Double-blind | 45.5 ± 15.72 | 44.3 ± 14.34 | 44.9 ± 15.02 |
| Years, Open-label | 45.7 ± 15.97 | 45.0 ± 14.25 | 45.3 ± 15.05 |
| Sex: Female, Male(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Double-Blind Sex — Female | 67 | 73 | 140 |
| Double-Blind Sex — Male | 42 | 36 | 78 |
| Open-Enrollment Sex — Female | 56 | 67 | 123 |
| Open-Enrollment Sex — Male | 37 | 36 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Ethnicity Double-Blind — Hispanic or Latino | 11 | 10 | 21 |
| Ethnicity Double-Blind — Not Hispanic or Latino | 95 | 96 | 191 |
| Ethnicity Double-Blind — Unknown or Not Reported | 3 | 3 | 6 |
| Ethnicity Open-Label — Hispanic or Latino | 8 | 10 | 18 |
| Ethnicity Open-Label — Not Hispanic or Latino | 82 | 91 | 173 |
| Ethnicity Open-Label — Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Double-blind Period — American Indian or Alaska Native | 1 | 0 | 1 |
| Double-blind Period — Asian | 2 | 5 | 7 |
| Double-blind Period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Double-blind Period — Black or African American | 1 | 0 | 1 |
| Double-blind Period — White | 103 | 100 | 203 |
| Double-blind Period — More than one race | 2 | 1 | 3 |
| Double-blind Period — Unknown or Not Reported | 0 | 3 | 3 |
| Open-label period — American Indian or Alaska Native | 1 | 0 | 1 |
| Open-label period — Asian | 0 | 4 | 4 |
| Open-label period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Open-label period — Black or African American | 1 | 0 | 1 |
| Open-label period — White | 89 | 95 | 184 |
| Open-label period — More than one race | 2 | 1 | 3 |
| Open-label period — Unknown or Not Reported | 0 | 3 | 3 |
| Weight (kg)(kg) | Elamipretide | Placebo | Total |
|---|---|---|---|
| Double-blind | 64.81 ± 20.287 | 67.24 ± 17.336 | 66.02 ± 18.865 |
| Open-label | 65.66 ± 20.867 | 68.01 ± 17.237 | 66.89 ± 19.033 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Feb 2020, 28 months.
Results were first posted in Apr 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →